Keryx Biopharmaceuticals, Inc. to Present at the Oppenheimer & Co. Inc. 25th Annual Healthcare Conference

NEW YORK, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present at the Oppenheimer & Co. Inc. 25th Annual Healthcare Conference, taking place December 10-11 in New York City.

Mr. Bentsur's presentation will take place on Thursday, December 11th at 8:35 a.m. ET, and will feature a general corporate overview, including an update on the Company's pending launch of Auryxia™ (ferric citrate).

A live audio webcast of Mr. Bentsur's presentation will be accessible within the Investor Relations section of the Company's website at An archived version of this webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's lead product, Auryxia™ (ferric citrate), was approved by the U.S. Food and Drug Administration on September 5, 2014.

For additional company information, including full prescribing information for Auryxia, please visit

CONTACT: Amy Sullivan, Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447; e-mail:

Source:Keryx Biopharmaceuticals, Inc.